Committed to developing novel vaccines against major infectious diseases and public health threats worldwide
Patronus Biotech, a subsidiary of Luye Life Sciences Group, focuses on the development, manufacturing and commercialization of new technology route vaccines and strives to be a pioneer in the industry.
With innovative vaccine core technology and an experienced team of scientists, Patronus has establisheda complete industrial chain from R&D, pilot test to commercialization.
Unique U-VLP (Universal VLP) platform
Breaks through the limitations of traditional VLP technology in pathogen types
Stable and high yield:
Breaks bottlenecks of traditional VLP manufacturing technology
Can be used for rapid development of a wide range of pathogenic vaccines, including emergency products such as COVID vaccine
Particle presentation improves the immunogenicity of otherwise poorly immunogenic protein antigens, together with steric presentation promotes conserved epitopes recognition thus higher broadly neutralising antibody titers